NEWS

News

May

11/05/2021

Philogen will be attending the PEGS Boston Virtual Summit from May 11^th to 13^th, 2021.
Alessandra Villa, Head of Antibody Research will give a lecture with the title “Targeted Immunocytokines” on May 12^th.
Samuele Cazzamalli, Head of Small Molecule Therapeutics will give a lecture with the title: “Small Molecule-Drug Conjugates: Getting Small to Enhance Targeting” on May 13^th.
 

06/05/2021

Philogen S.p.A. will announce its maiden First Quarter 2021 Results on Wednesday 12th May 2021

A virtual briefing will be hosted for sell-side analysts at 10:00am EST / 14:00pm BST / 15:00pm CEST on Thursday 13th May 2021

  PRESS RELEASE - Notice of Q1 Results

April

13/04/2021

Philogen announces publication of best-in-class FAP-targeting small molecule ligand (OncoFAP) in PNAS

Study shows impressive tumor uptake of OncoFAP with unprecedented selectivity against healthy organs
OncoFAP-based molecules are currently being developed for the imaging and therapy of cancer 

  PRESS RELEASE - PNAS

12/04/2021

Philogen announces publication of the construction and application of an innovative DNA- encoded chemical library in Nature Chemistry

Study shows the generation of a high-quality stereo- and regiodefined DNA-encoded chemical library.
Identified ligands against tumor-associated antigens can serve as vehicles for pharmacodelivery applications.
 

 

  PRESS RELEASE - NATURE CHEMISTRY

March

08/03/2021

Philogen will be attending the digital World ADC Europe Conference from March 8 to 11, 2021.
Dr. Samuele Cazzamalli - Head of Small Molecule Therapeutics - will give a Plenary Lecture on: “Small Molecule-Drug Conjugates: Getting Small to Enhance Targeting”.

January

22/01/2021

Philochem announces a publication entitled: “Immunotherapy with immunocytokines and PD-1 blockade enhances the anticancer activity of Small Molecule-Drug Conjugates targeting Carbonic Anhydrase IX”
Link to Paper

04/01/2021

Philochem is happy to announce the start of an Innosuissecollaboration with ETH Zurich for the development of Macrocyclic DualPharmacophore DNA-Encoded Chemical Libraries.
The partners will synthesize andvalidate macrocycle-based libraries comprising more than one billion compounds.
These libraries will have a great potential for the identification of ligandsagainst target proteins of biomedical interest with antibody-like properties